Argatroban monohydrate, >=98% (HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Argatroban monohydrate has been used as a thrombin-selective inhibitor in the thrombin assay of platelet poor plasma samples. It may be used as a standard in gradient reversed-phase liquid chromatography coupled with high-resolution multistage mass spectrometry (LC/HR-MSⁿ) for photoproducts fragmentation analysis and as a thrombin inhibitor competitive assay with fullerene-based C60 nanoparticle (NPs).

Biochem/physiol Actions

Argatroban has a high affinity and binds to arginine in thrombin active site resulting in steric hindrance for substrate binding. Argatroban is effective in preventing thrombus formation and favors thrombolysis than unfractionated heparin. It is recommended for acute ischemic stroke treatment.

Argatroban is a potent, seletive, univalent direct inhibitor of thrombin. It directly inhibits thrombin by binding only to its active site (thus univalent) as compared to Bivalent DTIs (hirudin and analogs) which bind both to the active site and exosite 1.

Features and Benefits

This compound was developed by Baxter. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Argatroban anticoagulant is synthesized from L-arginine and photodegrades under light exposure.

Packaging

5, 25 mg in glass bottle